UBS startles market with $14 billion writedown

UBS revealed this morning that it had taken even more damage from the US subprime debacle than it expected, with writedowns totalling $14 billion.

The Swiss bank will report $12 billion in fourth-quarter writedowns on its portfolio of assets linked to US subprime mortgages, and another $2 billion on assets linked to other US residential mortgages. It warned in December that it faced $10 billion in writedowns on its subprime mortgage holdings alone. This follows $4.4 billion in writedowns in the third quarter, and means the bank's subprime portfolio is now almost worthless - in its third-quarter results, the total residential mortgage-backed security portfolio was valued at $19 billion.

UBS will report its results in full on February 14, but said it would see a net loss of SFr12.5 billion for the quarter and SFr4.4 billion for the full year. In December, the bank warned it could see a loss for the full year.

The reasons for the writedown are still unclear, but rating agency Moody's criticised the bank's collateralised debt obligation (CDO) valuation methods in November. "Given the ongoing deterioration in the performance of the subprime collateral backing the CDOs, we expect the bank will likely need to take further meaningful writedowns on this portfolio. We have noted UBS is marking its super-senior CDOs to model, and this can currently lead to a lower level of markdowns than at banks that are referencing similar securities to the relevant ABX indexes," it wrote.

See also: UBS reports further $10 billion subprime writedowns
Moody's lowers UBS rating due to subprime fears 
UBS warns of continuing subprime risk 
UBS takes $3.4 billion hit

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here